Denmark could be first to produce a blockbuster obesity drug  

2006.12.06
A Danish biotech or pharmaceutical company could be among the first life science firms to launch a potential blockbuster drug for the treatment of obesity says president of IASO
A Danish biotech or pharmaceutical company could be among the first life science firms to launch a potential blockbuster drug for the treatment of obesity. So says Arne Astrup, president of the International Association for the Study of Obesity (IASO), and Professor at the Royal Veterinary and Agricultural University in Denmark.
 
"I sit on many advisory boards abroad where I can follow developments of new drugs. And from what I have seen, I think the quality in Denmark is high and that the chance for getting the drugs launched are higher for the Danish companies," says Astrup. He points especially to NeuroSearch and Novo Nordisk, both of which have compounds in early development.
 
One of Denmark's leading biotech investors, Florian Schönharting of Nordic Biotech, forecasts Novo Nordisk's compound Liraglutide to have a good future. "It is highly likely that the obesity compound from Novo Nordisk will be approved. It is without doubt that the compound can produce a weight loss, and it could become a giant hit with blockbuster potential."
 
In addition to the product from Novo Nordisk, Schönharting also highlights potential obesity drugs from NeuroSearch and 7TMPharma. The news was reported by professional journal Ingeniøren (The Engineer).

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×